We are live on ! Find out more
EVGN icon

Evogene
EVGN

16 hedge funds and large institutions have $10.8M invested in Evogene in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.05% less ownership

Funds ownership: 29.21% → 26.16% (-3%)

6% less funds holding

Funds holding: 17 → 16 (-1)

29% less capital invested

Capital invested by funds: $15.2M → $10.8M (-$4.43M)

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
8
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$26.8K

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$882K
2
MIH
Meitav Investment House
Israel
-$77.9K
3
UBS Group
UBS Group
Switzerland
-$62K
4
WRF
Waddell & Reed Financial
Kansas
-$57.5K
5
Goldman Sachs
Goldman Sachs
New York
-$40.3K

EVGN Hedge Fund Activity: Q4 2019 in Review

16 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2019, worth a combined $10.8M — down 29% from $15.2M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of EVGN and 0 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.

The largest buyer was ARK Investment Management, adding an estimated $26.8K. The largest seller was Clal Insurance, cutting an estimated $882K.

  • 16 institutional investors held Evogene (EVGN) as of Q4 2019, down from 17 in Q3 2019.
  • Funds reported $10.8M of Evogene stock for Q4 2019, down 29% quarter-over-quarter.
  • 0 funds opened new Evogene positions in Q4 2019 and 1 closed out, a net change of -1 holder.
  • The largest Evogene buyer in Q4 2019 was ARK Investment Management, an estimated $26.8K added.
  • The largest Evogene seller in Q4 2019 was Clal Insurance, an estimated $882K sold.

Based on aggregated 13F filings for Q4 2019.